New Moms Mood Tracking & Wellbeing

a study on Depression Anxiety Pregnancy

Summary

Eligibility
for females ages 18-65 (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Michelle Craske (ucla)

Description

Summary

New moms can be at risk for perinatal depression (PND). The New Moms Mood Tracking and Wellbeing study is investigating mood changes, risk factors for depression and anxiety and treatment response around the time of delivery. Participants will be asked to complete three sets of online surveys between week 28 gestation and week 20 after delivery, in addition to downloading an app to collect data using their smartphone sensors and brief symptom surveys every other week. Women with elevated symptoms can participate in treatment. Women will be randomized to one of two conditions - Perinatal Psychiatric Care or Screening and Treatment for Anxiety and Depression (STAND). In Perinatal Psychiatric Care, participants will receive appointments with psychiatry clinicians. In STAND, participants will be further allocated to Online therapy with Coaching or Clinical Care, which includes both psychotherapy and psychiatry appointments. Treatment can last up to 6 months and there will be treatment related assessments for the duration of the 6 months, in addition to brief symptom surveys on a regular basis. Therefore, participation can last between 24 and 52 weeks, as both time of delivery and treatment enrollment timepoint cannot be scheduled in advance.

Official Title

Perinatal Mood Tracking and Treatment

Keywords

Depression, Perinatal Depression, Anxiety, Pregnancy Related, Depressive Disorder, Online therapy with coaching, Clinical care

Eligibility

You can join if…

Open to females ages 18-65

  • Women who are between week 28 of their pregnancy and 6 months postpartum and are receiving care at a UCLA OB-GYN clinic
  • Fluent in English
  • Current endorsement of moderate or higher depression on the Edinburgh Postnatal Depression Scale (EPDS, => 11 sum score), administered by the treating OB-GYN physician or study staff
  • Not currently in individual treatment for a behavioral or emotional problem (e.g., anxiety, depression)
  • Willingness to follow study procedures
  • Willingness to participate in treatment through the study and follow all study procedures, including provide HIPAA Authorization for research
  • Has access to the internet via mobile or desktop device

You CAN'T join if...

  • Are currently receiving treatment by a therapist or a psychiatrist
  • Unstable suicidality (e.g., 2 or more suicide attempts or self-injurious behaviors resulting in hospitalization in the last 6 months, combined with high ratings on self-reported negative urgency)
  • Current substance use disorder that interferes with treatment: specifically, patients meeting diagnostic criteria for Substance Use Disorder (SUD) will be eligible for inclusion only if they are able to attend sessions while not under the influence of that substance, with the exception of individuals abusing opiates or freebase cocaine, who will be excluded
  • Principal diagnosis of psychosis unrelated to depression (unipolar or bipolar)
  • Neurological conditions
  • Severe uncontrolled medical conditions (e.g., anorexia nervosa, cardiac conditions requiring continuous monitoring)
  • Cognitive impairment (e.g., developmental disability, dementia)

Location

  • University of California, Los Angeles (UCLA) accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT05056454
Study Type
Interventional
Participants
Expecting 167 study participants
Last Updated